# Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

> **NCT06445062** · PHASE1,PHASE2 · RECRUITING · sponsor: **Revolution Medicines, Inc.** · enrollment: 1130 (estimated)

## Conditions studied

- Colorectal Cancer
- CRC
- Pancreatic Ductal Adenocarcinoma
- PDAC
- Gastrointestinal Cancer
- Metastatic Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** RMC-6236
- **DRUG:** mFOLFOX6 regimen
- **DRUG:** bevacizumab
- **DRUG:** mFOLFIRINOX regimen
- **DRUG:** cetuximab
- **DRUG:** gemcitabine
- **DRUG:** nab-paclitaxel
- **DRUG:** RMC-9805

## Key facts

- **NCT ID:** NCT06445062
- **Lead sponsor:** Revolution Medicines, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-24
- **Primary completion:** 2027-05-15
- **Final completion:** 2027-07-15
- **Target enrollment:** 1130 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06445062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06445062, "Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06445062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*